On March 15, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") reported the appointment of Dr. Xiong Zikai as the senior vice president (SVP) to be fully responsible for the company’s BD affairs (Press release, ImmuneOnco Biopharma, MAR 15, 2022, View Source [SID1234655641]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Zikai Xiong has extensive experience in various fields of biomedicine. Before joining ImmuneOnco, Dr. Xiong Zikai was in charge of strategic and innovative drug business development in Bayer Pharma, Lunsheng Pharma, Dino Pharma and other companies in Germany, and worked as a corporate strategic management consultant in Roland Berger, Germany. He also participated in the early entrepreneurial development of companies such as Genetron Health, an oncology in vitro diagnostic company.
Dr. Zikai Xiong holds a PhD in Cancer Molecular Genetics from the University of Cambridge, UK and a BS in Cell Biology and Genetics from Peking University.
Chairman and CEO, Dr. Tian, Wenzhi said: "I am very happy and sincerely welcome Dr. Xiong Zikai to join the ImmuneOnco team. I believe that, with his extensive professional experience, he will definitely help the company to develop rapidly. We also look forward to his joining to promote the business development of the company. ImmuneOnco accelerates the realization of the great vision of ‘developing first-class medicines for the benefit of cancer patients’". "We will work with all colleagues in the company to build the company into a world-renowned biopharmaceutical company and develop first-class new drugs for cancer patients around the world.